New research reveals that patients who stop using new slimming jabs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end traditional lifestyle plans.
Research printed in a prominent medical journal demonstrates that while obese individuals often shed a large proportion of their body weight while using the jabs, the mass comes back at an average rate of 0.8 kg per month once they quit.
"People purchasing these drugs need to be aware of the danger of quick rebound weight gain when the medication ends," stated expert Dr. Susan Jebb.
This pace of regain suggests a reversion to starting mass in about one and a half years.
Analyzing Therapies
The analysis, which looked at 37 of trials involving thousands of participants, contrasted the outcomes of these new drugs with older methods.
Scientists emphasize that people who lose weight through dieting typically see a less rapid creep back—approximately 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Doctors believe the way of the injections is key to understanding the accelerated regain.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone concentrations several times higher than normal may cause the system to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means appetite is no longer kept in check, making excessive eating a significant risk."
An Ongoing Disease?
The NHS advise the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes.
Many experts say that, considering the likelihood of weight regain, the therapy might need to be ongoing.
This perspective is supported by drug manufacturers, who say that the findings "highlight the persistent character of excess weight," similar to managing diseases like hypertension.
Patient Experiences
Users who have discontinued the jabs explain a intense resurgence of cravings.
"It was like a switch activating and you're instantly ravenous," recalled a patient.
This difficulty is compounded if patients have not established permanent dietary or behavioural modifications during treatment.
Widespread Use
Survey data indicate that a significant number of adults in the UK have used these injections in the last 12 months, with interest being substantial.
- Adoption is more common among females compared to men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while these medications are potent tools for weight loss, they are not a permanent fix and lasting health benefits hinges on ongoing behavioural support.
